Abecma Approved for Earlier Lines in R/R Multiple Myeloma :

The drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens.

Related Keywords

Bristol Myers Squibb , Drug Administration , Multiple Myeloma , Myeloma , Plasma Cell Myeloma , Chimeric Antigen Receptort Cell Therapy , Chimeric Antigen Receptors , Himeric Immunoreceptors , Himerict Cell Receptors , Rtificialt Cell Receptors , Art Chimaeric Antigen Receptort Cell Therapy Receptors Immunoreceptors Chimaerict , Biologic Therapy , Iologics , Cytokines , Antigens , Cancer ,